ATE223726T1 - Formulierung zur peptidfreisetzung - Google Patents

Formulierung zur peptidfreisetzung

Info

Publication number: ATE223726T1
Authority: AT; Austria
Prior art keywords: formulation; release formulation; deslorelin; peptide release; mug
Prior art date: 1995-06-20

Application number

AT96917292T

Other languages

English (en)

Inventor

John Desmond Walsh

Timothy Elliot Trigg

Original Assignee

Peptech Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-20

Filing date

1996-06-20

Publication date

2002-09-15

1996-06-20 Application filed by Peptech Ltd filed Critical Peptech Ltd

2002-09-15 Application granted granted Critical

2002-09-15 Publication of ATE223726T1 publication Critical patent/ATE223726T1/de

Links

238000009472 formulation Methods 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
108090000765 processed proteins & peptides Proteins 0.000 title 1
GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 abstract 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
229960005408 deslorelin Drugs 0.000 abstract 2
108700025485 deslorelin Proteins 0.000 abstract 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
241000282472 Canis lupus familiaris Species 0.000 abstract 1
241000282326 Felis catus Species 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
230000009286 beneficial effect Effects 0.000 abstract 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229960005309 estradiol Drugs 0.000 abstract 1
229930182833 estradiol Natural products 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000002953 phosphate buffered saline Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
210000002307 prostate Anatomy 0.000 abstract 1
230000001850 reproductive effect Effects 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1
229960003604 testosterone Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Steroid Compounds (AREA)

AT96917292T 1995-06-20 1996-06-20 Formulierung zur peptidfreisetzung ATE223726T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPN3667A AUPN366795A0 (en)	1995-06-20	1995-06-20	Formulation for preventing reproductive function
PCT/AU1996/000370 WO1997000693A1 (en)	1995-06-20	1996-06-20	Novel formulation for peptide release

Publications (1)

Publication Number	Publication Date
ATE223726T1 true ATE223726T1 (de)	2002-09-15

Family

ID=3788008

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96917292T ATE223726T1 (de)	1995-06-20	1996-06-20	Formulierung zur peptidfreisetzung

Country Status (16)

Country	Link
US (2)	US5925619A (de)
EP (1)	EP0871467B1 (de)
JP (1)	JP4016133B2 (de)
CN (1)	CN1145496C (de)
AT (1)	ATE223726T1 (de)
AU (2)	AUPN366795A0 (de)
CA (1)	CA2225796C (de)
DE (2)	DE122008000004I2 (de)
DK (1)	DK0871467T3 (de)
ES (1)	ES2182983T3 (de)
FR (1)	FR08C0001I2 (de)
NL (1)	NL300330I2 (de)
NZ (1)	NZ309697A (de)
PT (1)	PT871467E (de)
SI (1)	SI0871467T1 (de)
WO (1)	WO1997000693A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPN366795A0 (en) *	1995-06-20	1995-07-13	Peptide Technology Limited	Formulation for preventing reproductive function
NZ334236A (en) *	1996-08-30	2000-06-23	Peptech Ltd	Composition comprising GnRH, lecithin and stearin
US6913761B1 (en) *	1998-07-20	2005-07-05	Peptech Limited	Bioimplant formulation
US8052982B2 (en) *	1998-07-20	2011-11-08	Peptech Animal Health Pty Limited	Bioimplant formulation comprising lecithin and stearin
US6211221B1 (en) *	1999-04-05	2001-04-03	Johnny W. Peterson	Dietary supplement containing histidine for alleviating dysmenorrhea, endometriosis, and pre-term labor
EP1330257B1 (de) *	2000-10-30	2005-08-31	University Of Zurich	Verwendung von gnrh-analogue zur behandlung der harninkontinenz
GB0221539D0 (en) *	2002-09-17	2002-10-23	Medical Res Council	Methods of treatment
CA2552241C (en) *	2003-12-30	2013-10-01	Durect Corporation	Co-polymeric devices for controlled release of active agents
US20080254086A1 (en) *	2004-12-23	2008-10-16	Brown James E	Controlled Release Compositions
US20100184698A1 (en) *	2007-09-11	2010-07-22	Dorian Bevec	Use of a deslorelin and mastoparan as a therapeutic agent
DE102008015104A1 (de)	2008-03-19	2009-09-24	Basf Coatings Ag	Beschichtungszusammensetzung, Verfahren zu ihrer Herstellung, ihre Verwendung und mit ihr beschichtete Substrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS563846B2 (de) *	1972-10-12	1981-01-27
US4218439A (en) *	1977-07-14	1980-08-19	The Salk Institute For Biological Studies	Peptide which inhibits gonadal function
US4256737A (en) *	1979-06-11	1981-03-17	Syntex (U.S.A.) Inc.	Long acting depot injectable formulations for LH-RH analogues
CA1257199A (en) *	1986-05-20	1989-07-11	Paul Y. Wang	Preparation containing bioactive macromolecular substance for multi-months release in vivo
ES2039219T3 (es) *	1986-08-11	1993-09-16	American Cyanamid Company	Composiciones para administracion parenteral y su uso.
US4897268A (en) *	1987-08-03	1990-01-30	Southern Research Institute	Drug delivery system and method of making the same
US5538739A (en) *	1989-07-07	1996-07-23	Sandoz Ltd.	Sustained release formulations of water soluble peptides
US5211952A (en) *	1991-04-12	1993-05-18	University Of Southern California	Contraceptive methods and formulations for use therein
US5470582A (en) *	1992-02-07	1995-11-28	Syntex (U.S.A.) Inc.	Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
AUPN366795A0 (en) *	1995-06-20	1995-07-13	Peptide Technology Limited	Formulation for preventing reproductive function

1995
- 1995-06-20 AU AUPN3667A patent/AUPN366795A0/en not_active Abandoned
1996
- 1996-06-20 JP JP50345797A patent/JP4016133B2/ja not_active Expired - Lifetime
- 1996-06-20 PT PT96917292T patent/PT871467E/pt unknown
- 1996-06-20 US US08/981,285 patent/US5925619A/en not_active Expired - Lifetime
- 1996-06-20 AT AT96917292T patent/ATE223726T1/de active
- 1996-06-20 ES ES96917292T patent/ES2182983T3/es not_active Expired - Lifetime
- 1996-06-20 WO PCT/AU1996/000370 patent/WO1997000693A1/en not_active Ceased
- 1996-06-20 SI SI9630524T patent/SI0871467T1/xx unknown
- 1996-06-20 DE DE122008000004C patent/DE122008000004I2/de active Active
- 1996-06-20 AU AU59927/96A patent/AU701837B2/en not_active Expired
- 1996-06-20 DE DE69623652T patent/DE69623652T2/de not_active Expired - Lifetime
- 1996-06-20 EP EP96917292A patent/EP0871467B1/de not_active Expired - Lifetime
- 1996-06-20 CN CNB961948647A patent/CN1145496C/zh not_active Expired - Lifetime
- 1996-06-20 NZ NZ309697A patent/NZ309697A/xx not_active IP Right Cessation
- 1996-06-20 DK DK96917292T patent/DK0871467T3/da active
- 1996-06-20 CA CA2225796A patent/CA2225796C/en not_active Expired - Lifetime
1999
- 1999-02-17 US US09/251,411 patent/US6211152B1/en not_active Expired - Lifetime
2008
- 2008-01-08 NL NL300330C patent/NL300330I2/nl unknown
- 2008-01-10 FR FR08C0001C patent/FR08C0001I2/fr active Active

Also Published As

Publication number	Publication date
ES2182983T3 (es)	2003-03-16
JP4016133B2 (ja)	2007-12-05
DE69623652D1 (de)	2002-10-17
SI0871467T1 (en)	2003-08-31
NZ309697A (en)	1999-11-29
AU5992796A (en)	1997-01-22
HK1014874A1 (en)	1999-10-08
DK0871467T3 (da)	2002-12-23
CN1188414A (zh)	1998-07-22
AUPN366795A0 (en)	1995-07-13
JP2001521482A (ja)	2001-11-06
DE69623652T2 (de)	2003-05-28
WO1997000693A1 (en)	1997-01-09
US5925619A (en)	1999-07-20
CN1145496C (zh)	2004-04-14
DE122008000004I2 (de)	2009-08-06
CA2225796A1 (en)	1997-01-09
EP0871467A4 (de)	2000-07-05
AU701837B2 (en)	1999-02-04
CA2225796C (en)	2011-09-20
EP0871467A1 (de)	1998-10-21
NL300330I2 (nl)	2008-04-01
DE122008000004I1 (de)	2008-04-17
US6211152B1 (en)	2001-04-03
FR08C0001I2 (de)	2009-11-20
PT871467E (pt)	2002-12-31
EP0871467B1 (de)	2002-09-11
NL300330I1 (nl)	2008-03-03
FR08C0001I1 (de)	2008-03-21

Legal Events

Date

Code

Title

Description

2003-02-15

UEP

Publication of translation of european patent specification

Ref document number: 0871467

Country of ref document: EP

2009-11-15

EEIH

Change in the person of patent owner

Publication	Publication Date	Title
FR08C0001I2 (de)	2009-11-20
AU4718496A (en)	1996-09-11	Use of aerogels in agriculture
MY113488A (en)	2002-03-30	Compounds with growth hormone releasing properties
AU560829B2 (en)	1987-04-16	Continuous release pharmaceutical compositions
DE69925936D1 (de)	2005-07-28	Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle
NZ283135A (en)	2004-12-24	Gel formulation for treatment of skin diseases and disinfection/disinfestation of the skin
ES2050070B1 (es)	1994-10-01	Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.
CA2223817A1 (en)	1999-06-05	Compositions for the treatment of rheumatoid-based arthritic diseases
MY138883A (en)	2009-08-28	Use of asiatic acid for treatment of cencer
IL107153A (en)	2000-07-16	Pharmaceutical compositions for preventing insulin-dependent diabetes mellitus comprising IL10 and method for their manufacture
BR9607541A (pt)	1997-12-23	Tratamento de doenças que tem por causa o fator de crescimento da citoquina
AU5643299A (en)	2000-04-10	Humic acid and its use in the treatment of various conditions
DE60005952T8 (de)	2004-11-04	Lösliche hla-g enthaltende zusammensetzungen zur behandlung entzündlicher hautkrankheiten
PL318130A1 (en)	1997-05-12	Terpenod derivatives (of sarcodictyine)as antineoplastic agents
OA09771A (en)	1993-11-30	Asphodelus composition for increasing white blood cell count.
BG101173A (en)	1998-10-30	Vaccine against pasteurellosis and haemorrhagic disease in rabbits
MY114109A (en)	2002-08-30	The use of bioassimilable boron compounds
UA30723A (uk)	2000-12-15	Спосіб лікування аутоімунних захворювань
UA36126A (uk)	2001-04-16	Бандаж поперековий
BG51699A1 (en)	1993-08-16	Stimulating fertility agent
IT1245148B (it)	1994-09-13	Glicoproteine estratte da apparati riproduttori femminili, loro uso in dermatologia e cosmesi della pelle e delle mucose
GR1002955B (el)	1998-08-07	Προιοντα που προερχονται απο το φυτο κυπαρισσος και ολα τα συγγενη κωνοφορα, για χρηση στην προληψη και θεραπεια καθε τυπου υπερχοληστεριναιμιας και διαταραχης λιπιδιων, σε ανθρωπους και ζωα